Differences in SARS-CoV-2-Specific Antibody Responses After the First, Second, and Third Doses of BNT162b2 in Naïve and Previously Infected Individuals: A 1-Year Observational Study in Healthcare Professionals

BACKGROUND: Safe and effective vaccines against COVID-19 are critical for preventing the spread of SARS-CoV-2, but little is known about the humoral immune response more than 9 months after vaccination. We aimed to assess the humoral immune response after the first, second, and third (booster) doses...

Descripción completa

Detalles Bibliográficos
Autores principales: Ogrič, Manca, Žigon, Polona, Podovšovnik, Eva, Lakota, Katja, Sodin-Semrl, Snezna, Rotar, Žiga, Čučnik, Saša
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2022
Materias:
Immunology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9196038/
https://www.ncbi.nlm.nih.gov/pubmed/35711413
http://dx.doi.org/10.3389/fimmu.2022.876533

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9196038/
https://www.ncbi.nlm.nih.gov/pubmed/35711413
http://dx.doi.org/10.3389/fimmu.2022.876533

Ejemplares similares